Inhibitori različitih protein-kinaza

master's thesis

• Title (english): Inhibitors of various protein kinases
• Author: Zrinka Slamić
• Mentor: Kristina Pavić (mentor)
• Committee member: Kristina Pavić (predsjednik povjerenstva)
• Committee member: Zrinka Rajić (član povjerenstva)
• Committee member: Davor Šakić (član povjerenstva)
• Granter: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of medicinal chemistry); Zagreb
• Defense date and country: 2021-09-20, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract

U ovom radu obrađeni su inhibitori receptora za epidermalni faktor rasta (EGFR) kao i inhibitori Bcr-Abl
kinaze, fosfoinozitid-3-kinaze i Janus kinaze te inhibitori Hedgehog signalnog puta. U općem pregledu
navedenih protein-kinaza istaknuti su bitni elementi svake skupine. Dan je uvid u signalni put svake navedene
kinaze te pregled nekoliko odobrenih inhibitora na tržištu. Zatim je na konkretnim primjerima objašnjena
struktura lijeka, važnost određenih dijelova strukture za djelovanje te je opisan sintetski put.
Lijekovi obrađeni u ovom radu su:
1) inhibitori EGFR: neratinib i osimertinib,
2) Bcr-Abl inhibtori: nilotinib i ponatinib,
3) PI3K inhibitori: alpelisib i idelalisib,
4) JAK inhibitori: ruksolitinib i fedratinib,
5) Hedgehog inhibitori: sonidegib i vismodegib.

Abstract (english)

In this diploma thesis, epidermal growth factor receptor (EGFR) inhibitors, as well as BCR-Ab1 kinase,
phosphoinositide-3-kinase, Janus kinase, and Hedgehog signaling pathway inhibitors, are discussed. The
most important facts are highlighted for each protein kinase. An insight into the protein kinase signaling
pathways and an overview of approved inhibitors are given. Furthermore, drug structures, structure-activity
relationships, and synthetic routes are explained in specific examples.
The following drugs are described in detail in this thesis:
1) EGFR inhibitors: neratinib and osimertinib,
2) Bcr-Abl inhibitors: nilotinib and ponatinib,
3) PI3K inhibitors: alpelisib and idelalisib,
4) JAK inhibitors: ruxolitinib and fedratinib,
5) Hedgehog inhibitors: sonidegib and vismodegib.

• Keywords: protein-kinaza; EGFR; Bcr-Abl kinaza; JAK; PI3K; Hedgehog signalni put
• Keywords (english): protein-kinase; EGFR; Bcr-Abl kinase; JAK; PI3K; Hedgehog signaling pathway
• Language: croatian
• URN:NBN: urn:nbn:hr:163:099986
• Study programme: Title: Pharmacy; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: magistar/magistra farmacije (magistar/magistra farmacije)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2022-03-28 13:50:17